Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial

CONTEXT: Control of multiple cardiovascular (CV) risk factors reduces CV events in individuals with type 2 diabetes. OBJECTIVE: To investigate this association in a contemporary clinical trial population, including how CV risk factor control affects the CV benefits of empagliflozin, a sodium-glucose...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Endocrinol Metab
Auteurs principaux: Inzucchi, Silvio E, Khunti, Kamlesh, Fitchett, David H, Wanner, Christoph, Mattheus, Michaela, George, Jyothis T, Ofstad, Anne Pernille, Zinman, Bernard
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2020
Sujets:
Clinical Research Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7382052/
https://ncbi.nlm.nih.gov/pubmed/32485734
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/clinem/dgaa321
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires